Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1999-6-15
pubmed:abstractText
Treatment of Hodgkin's disease in children should be directed at maximizing cures and minimizing the long-term effects of alkylating agents, anthracyclines, and bleomycin. In this study methotrexate and etoposide were used in the VAMP/VEPA regimens to treat 60 clinically staged pediatric patients with Hodgkin's disease. Twenty-nine patients with stages I-IIA received four courses of VAMP plus low-dose radiotherapy. Thirty-one IIA bulky disease and IIB-IVB patients received four or six courses of VEPA plus low-dose radiotherapy. There were 6 partial remissions after the completion of chemotherapy and all of these patients relapsed, but 4 were successfully salvaged with ABMT. Two patients have died. The 3.1-year overall survival rate is 97% (100% VAMP, 94% VEPA) and the event-free survival rate is 88% (97% VAMP, 77% VEPA). These results suggest that VAMP is a reasonable treatment for low stages of Hodgkin's disease, but more advanced disease is not adequately treated by VEPA and low-dose radiotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0888-0018
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
141-8
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:10100274-Adolescent, pubmed-meshheading:10100274-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10100274-Child, pubmed-meshheading:10100274-Child, Preschool, pubmed-meshheading:10100274-Combined Modality Therapy, pubmed-meshheading:10100274-Cyclophosphamide, pubmed-meshheading:10100274-Disease-Free Survival, pubmed-meshheading:10100274-Dose-Response Relationship, Radiation, pubmed-meshheading:10100274-Doxorubicin, pubmed-meshheading:10100274-Female, pubmed-meshheading:10100274-Hodgkin Disease, pubmed-meshheading:10100274-Humans, pubmed-meshheading:10100274-Male, pubmed-meshheading:10100274-Methotrexate, pubmed-meshheading:10100274-Prednisolone, pubmed-meshheading:10100274-Procarbazine, pubmed-meshheading:10100274-Retrospective Studies, pubmed-meshheading:10100274-Survival Rate, pubmed-meshheading:10100274-Vincristine
pubmed:articleTitle
Treatment of Hodgkin's disease in children with VAMP (vinblastine, adriamycin, methotrexate, prednisone) and VEPA (vinblastine, etoposide, prednisone, adriamycin).
pubmed:affiliation
Department of Pediatric Oncology, Charles University Hospital Motol, Prague, Czech Republic. petr.kavan@lfmotol.cuni.cz
pubmed:publicationType
Journal Article